We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+24.34%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.08B
AUM Growth
-$1.3B
(-39%)
Cap. Flow
-$1.79B
Cap. Flow
% of AUM
-86.14%
Top 10 Holdings %
Top 10 Hldgs %
46.37%
Holding
64
New
8
Increased
12
Reduced
35
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$41.5M |
| 2 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$23.2M |
| 3 |
Celldex Therapeutics
CLDX
|
+$21.6M |
| 4 |
Pfizer
PFE
|
+$19.8M |
| 5 |
OMED
OncoMed Pharmaceuticals, Inc.
OMED
|
+$19.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$151M |
| 2 |
Viatris
VTRS
|
+$125M |
| 3 |
Boston Scientific
BSX
|
+$123M |
| 4 |
AGN
Allergan plc
AGN
|
+$123M |
| 5 |
Edwards Lifesciences
EW
|
+$118M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 86.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
DexCom
DXCM
$28.9B
| $5.49M | 0.26% |
778,632
-5,713,564
| -88% | -$36.2M |
|
|
NVO
52
Novo Nordisk
NVO
$225B
| $3.35M | 0.16% |
197,760
+29,750
| +18% | +$500K |
|
53
PTC Therapeutics
PTCT
$6.25B
| $1.23M | 0.06% |
57,519
-28,581
| -33% | -$497K |
|
|
ACHN
54
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.16M | 0.06% |
384,300
-1,130,400
| -75% | -$7.75M |
|
55
Novartis
NVS
$304B
| $844K | 0.04% |
12,276
+2,567
| +26% | +$170K |
|
|
AMRN
56
Amarin Corp
AMRN
$293M
| – | – |
-90,876
| Closed | -$10.5M |
|
|
57
Edwards Lifesciences
EW
$48.2B
| – | – |
-10,551,822
| Closed | -$118M |
|
58
Eli Lilly
LLY
$1.09T
| – | – |
-1,288,250
| Closed | -$63.3M |
|
59
United Therapeutics
UTHR
$26.1B
| – | – |
-321,032
| Closed | -$21.1M |
|
|
VAR
60
DELISTED
Varian Medical Systems, Inc.
VAR
| – | – |
-962,875
| Closed | -$57M |
|
|
SQNM
61
DELISTED
SEQUENOM INC NEW
SQNM
| – | – |
-4,103,868
| Closed | -$17.3M |
|
|
THOR
62
DELISTED
THORATEC CORPORATION
THOR
| – | – |
-470,118
| Closed | -$14.7M |
|
|
FRX
63
DELISTED
FOREST LABORATORIES INC
FRX
| – | – |
-283,075
| Closed | -$11.6M |
|
|
ONXX
64
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| – | – |
-1,356,043
| Closed | -$118M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q3 2013 Portfolio in Review
As of Q3 2013, Sectoral Asset Management held 64 positions worth $2.08B, down 39% from $3.38B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Sectoral Asset Management withdrew a net $1.79B in Q3 2013, closing 9 positions and reducing 35 holdings. Its most notable exit was Edwards Lifesciences, an estimated $118M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 84% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $29.9M.
- Sectoral Asset Management's largest Q3 2013 buy was SYNAGEVA BIOPHARMA CORP COM STK (DE): 470,950 shares worth $29.9M.
- Sectoral Asset Management added most to Amgen in Q3 2013, an estimated $41.5M increase.
- Sectoral Asset Management's biggest Q3 2013 reduction was Incyte, cutting an estimated $151M.
- Sectoral Asset Management fully exited Edwards Lifesciences in Q3 2013, selling an estimated $118M.
- Sectoral Asset Management's ten largest holdings make up 46% of its $2.08B portfolio in Q3 2013.
- Sectoral Asset Management opened 8 new positions and closed 9 in Q3 2013.
- Sectoral Asset Management's portfolio value fell 39% quarter-over-quarter to $2.08B.
Based on Sectoral Asset Management's 13F filing for Q3 2013, filed 13 Nov 2013.